Patients in the Netherlands wait 1.5 years for access to new medicines

2 September 2021 - Patients in the Netherlands have to wait an average of 510 days for access to a new ...

Read more →

Hansa Biopharma announces reimbursement in the Netherlands of Idefirix (imlifidase) as desensitisation treatment for highly sensitised kidney transplant patients

2 August 2021 - Idefiris (imlifidase) for enabling kidney transplantation in highly sensitised patients is now reimbursable and available for use ...

Read more →

Dutch advisory group says Zolgensma shouldn’t be covered unless Novartis halves price

10 May 2021 - In a challenge to Novartis, a Dutch advisory body has recommended that the government not cover ...

Read more →

World’s most expensive drug may not be covered by Dutch insurance

7 May 2021 - A drug to treat a rare muscle disease which affects some 20 children in the Netherlands ...

Read more →

Ineffective treatments to be removed from basic health insurance package

5 October 2020 - Treatments that have not been proven effective will be removed from the Netherlands' basic health insurance package, ...

Read more →

Did a pharma trade group try to sabotage a Dutch government report on compulsory licensing?

7 July 2020 - Dutch government commission on compulsory licensing was nearly sabotaged last month after one of its members ...

Read more →

Celltrion’s Remsima SC launches in Netherlands

7 May 2020 - Subcutaneous rheumatoid arthritis treatment Remsima SC launched in the Netherlands, its third European market, Celltrion Healthcare ...

Read more →

Five pillars for societal perspective

31 January 2020 - In economic evaluation, the healthcare perspective has gradually given way to use of the societal perspective, as ...

Read more →

DIY drugs: should hospitals make their own medicine?

15 October 2019 - If pharmaceutical companies rapidly inflate the price of their products, is there an alternative? One Dutch chemist ...

Read more →

Dutch experience demonstrates effective benchmarking of biosimilar use in health systems

31 August 2019 - As medicines become more numerous and often more expensive, health care professionals seek new ways to understand ...

Read more →

Dutch health minister threatens to name and shame pharma over prices

28 August 2019 - In an unusual move, the Netherlands health minister wrote an open letter to the pharmaceutical industry ...

Read more →

Dutch minister warns big pharma to come clean on drugs prices

27 August 2019 - Health minister Bruno Bruins has warned the pharmaceuticals industry that he considers the way drugs firms ...

Read more →

Implementation of “coverage with evidence development” drug approval strategies found lacking

15 July 2019 - Lessons from early deployments in The Netherlands. ...

Read more →

Taxpayers are funding expensive drug development, report says

10 May 2019 - The Dutch government invests tens of millions of euros every year in small biotech companies which ...

Read more →

Beneluxa: what are the prospects for collective bargaining on pharmaceutical prices given diverse health technology assessment processes?

23 April 2019 - The Beneluxa collaboration is an initiative aimed at securing sustainable access to new medicines.  ...

Read more →